CRSP Q2 EPS Forecast Lifted by Brookline Capital Acquisition

CRISPR Therapeutics AG (NASDAQ:CRSP) – Research analysts at Brookline Capital Acquisition increased their Q2 2026 earnings per share estimates for shares of CRISPR Therapeutics in a research report issued on Wednesday, March 11th. Brookline Capital Acquisition analyst L. Cann now anticipates that the company will post earnings per share of ($1.16) for the quarter, up from their prior estimate of ($1.22). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share. Brookline Capital Acquisition also issued estimates for CRISPR Therapeutics’ Q3 2026 earnings at ($1.40) EPS, Q4 2026 earnings at ($1.31) EPS, FY2026 earnings at ($4.96) EPS and FY2027 earnings at ($5.51) EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Thursday, February 12th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.22). The business had revenue of $0.86 million for the quarter, compared to analysts’ expectations of $4.72 million. CRISPR Therapeutics had a negative return on equity of 26.31% and a negative net margin of 16,569.77%.CRISPR Therapeutics’s quarterly revenue was down 97.8% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.01) EPS.

Several other research analysts have also recently weighed in on CRSP. Morgan Stanley restated an “underweight” rating and set a $33.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, February 17th. Evercore reaffirmed an “outperform” rating and issued a $74.00 price target on shares of CRISPR Therapeutics in a report on Friday, February 13th. TD Cowen lifted their price objective on CRISPR Therapeutics from $40.00 to $45.00 and gave the stock a “hold” rating in a research report on Friday, February 13th. Citigroup reissued a “buy” rating on shares of CRISPR Therapeutics in a research note on Monday, February 16th. Finally, Bank of America dropped their target price on CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating for the company in a report on Thursday, January 22nd. Ten research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $64.24.

CRISPR Therapeutics Trading Down 0.2%

Shares of NASDAQ CRSP opened at $48.75 on Friday. The stock has a market cap of $4.68 billion, a PE ratio of -7.48 and a beta of 1.72. CRISPR Therapeutics has a 12-month low of $30.04 and a 12-month high of $78.48. The company has a 50-day moving average of $54.10 and a 200 day moving average of $57.26.

Institutional Trading of CRISPR Therapeutics

Several institutional investors have recently added to or reduced their stakes in CRSP. Mcguire Capital Advisors Inc. purchased a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at $25,000. Ramirez Asset Management Inc. acquired a new position in CRISPR Therapeutics in the 4th quarter valued at about $26,000. Rothschild Investment LLC increased its stake in CRISPR Therapeutics by 836.7% during the fourth quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock worth $29,000 after purchasing an additional 502 shares during the period. Thurston Springer Miller Herd & Titak Inc. lifted its position in shares of CRISPR Therapeutics by 196.9% during the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock worth $30,000 after purchasing an additional 382 shares in the last quarter. Finally, Thompson Investment Management Inc. acquired a new stake in shares of CRISPR Therapeutics during the third quarter worth about $33,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

Insider Transactions at CRISPR Therapeutics

In related news, General Counsel James R. Kasinger sold 2,800 shares of the business’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $52.80, for a total value of $147,840.00. Following the sale, the general counsel directly owned 87,815 shares in the company, valued at approximately $4,636,632. The trade was a 3.09% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Samarth Kulkarni sold 9,798 shares of the company’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $52.80, for a total transaction of $517,334.40. Following the completion of the transaction, the chief executive officer directly owned 235,558 shares in the company, valued at $12,437,462.40. The trade was a 3.99% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 111,677 shares of company stock valued at $6,308,848 over the last three months. Corporate insiders own 4.30% of the company’s stock.

Key CRISPR Therapeutics News

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: FY‑2025 commercial progress: management reported $116M in FY‑25 revenue driven by CASGEVY, including $54M in Q4, which supports the company’s early commercial trajectory and longer‑term revenue potential. Read More.
• Positive Sentiment: Institutional buying noted: coverage flagged that ARK Invest added CRSP stock, indicating renewed institutional interest that can provide buying support and liquidity. Read More.
• Positive Sentiment: Analyst estimate tweaks: Brookline Capital made small near‑term EPS adjustments (slightly less negative for FY‑2026/FY‑2027), a modest constructive signal for near‑term earnings expectations.
• Neutral Sentiment: Elevated retail interest: Zacks/Yahoo highlighted CRSP among most‑searched stocks — this increases volatility potential but is not a directional fundamental driver. Read More.
• Neutral Sentiment: Short‑interest data appears noisy: recent feeds show inconsistent/zero short‑interest figures (likely data artifacts) and do not provide a clear positioning read.
• Negative Sentiment: Convertible senior notes offering: CRISPR priced an upsized $550M convertible notes deal due 2031. Large convertibles can pressure shares (dilution risk, added supply) and were the proximate cause of a sharp intraday sell‑off. Read More.
• Negative Sentiment: Insider selling: CEO Samarth Kulkarni and General Counsel James Kasinger disclosed sales (roughly 9,798 and 2,800 shares) on March 11th; while routine SEC filings often reflect diversification or scheduled plans, investors frequently interpret such sales as negative near‑term signals. Read More.
• Negative Sentiment: Recent price weakness and volatility: media reported multi‑percent intraday declines following the financing announcement, which can trigger momentum selling and keep downward pressure on the stock. Read More.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.